COMP <GO>
KNSA vs MRK // 10Y YIELD & FRED MACRO BETA
Kiniksa Pharmaceuticals International plc Class A (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: KNSA 6
— MRK 9
▲ 10Y YIELD & FRED MACRO BETA LEADER: KNSA
LAST: $92.24 (-5.45%) • MKT CAP: $7.67B
macro-sensitivity
1.11
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KNSA | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.50% | 74.80% | +13.70 | KNSA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 20.70% | -10.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 15.3x | +79.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.78% | 3.42% | -1.64 | MRK | /fcf-yield <GO> |
| Operating Margin | 11.40% | 34.30% | -22.90 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.70% | 28.10% | -19.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 60.10% | 1.30% | +58.80 | KNSA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 24.45 | 5.19 | +19.26 | KNSA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | KNSA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.60% | +0.70 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.0 | 56.9 | +6.12 | KNSA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.11 | 0.92 | +0.19 | KNSA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 109.1x | 18.4x | +90.70 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.67B | $361.02B | -$353.36B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KNSA REV | MRK REV | KNSA GROSS % | MRK GROSS % | KNSA FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $677.6M | $65.01B | 88.5% | 74.8% | $136.4M | $12.36B |
| FY 2024 | $423.2M | $64.17B | 85.6% | 76.3% | $25.4M | $18.10B |
| FY 2023 | $270.3M | $60.12B | 44.0% | 44.0% | $1.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
MRK // BETA 0.92